On Wednesday, Silicon Motion Technology Corp. (NASDAQ:SIMO)’s shares gained 9.91%, and closed at $30.49, hitting new 52-week high of $30.50, after a fabless semiconductor corporation, declared that based upon its preliminary first quarter financial results, proceed is predictable to be roughly flat sequentially, at the high-end of its original guidance range of a sequential decline of 5% to 0% that the corporation issued on January 27, 2015. Gross margin (non-GAAP) is predictable to be within 51 to 52%, at the high-end of the corporation’s original guidance range of 50 to 52%.
The Corporation will release its full first quarter 2015 results after the market closes on April 27, 2015. The Corporation will host a conference call on April 28, at 8 am Eastern Time, to talk about its results.
Silicon Motion Technology Corporation, a fabless semiconductor corporation, designs, develops, and markets semiconductor solutions for mobile storage and mobile communications markets.
Athersys, Inc. (NASDAQ:ATHX)’s shares jumped 9.47%, and settled at $3.12, during the last trading session on Wednesday, after a biotechnology corporation, declared that Dr. David Hess, a stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia Regents University, and the lead principal investigator in the study, will present the preliminary results from its Phase 2 clinical trial administering MultiStem(R) for the treatment of ischemic stroke. The presentation will take place at the European Stroke Organization Conference (ESOC) 2015 on Sunday, April 19th starting at 8:50 am in Glasgow, Scotland, United Kingdom. Dr. Hess’ presentation will be in the Boisdale Room of the Scottish Exhibition and Conference Centre in Glasgow, in the conference venue.
Athersys’ double-blind, placebo-controlled Phase 2 clinical trial is being conducted at leading stroke centers across the United States and in the United Kingdom to evaluate the safety and efficacy of its proprietary MultiStem cell therapy in adults who have suffered a severe ischemic stroke and are treated 24-48 hours following the stroke. Dr. Hess served as the lead clinician for the Phase 2 clinical trial, which also comprised of clinical research teams from Oregon Health Sciences University, Houston Methodist Hospital, University of Pittsburgh Medical Center, Cleveland Clinic, Newcastle Upon Tyne and Stoke on Trent, among others. Trial enrollment was accomplished in December 2014 and this will be the first presentation of the unblinded results.
Athersys, Inc., a biotechnology corporation, focuses on the research and development activities in the field of regenerative medicine. The corporation’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has accomplished Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-as compared to-host disease.
At the end of Wednesday’s trade, Dyax Corp. (NASDAQ:DYAX)’s shares climbed 8.54%, and closed at $30.45, hitting new 52-week high of $30.55, as with promising results of a single early-stage trial last week, a 124-employee Burlington biotech working on a drug for a disease few people have ever heard of has suddenly become worth more on the stock market than the state’s best-known beer maker.
Among local biotech companies, Dyax — which has one drug on the market called Kalbitor which brought in $68 million in proceed last year — has become the fourth most valuable biotech in the state as of this afternoon, trailing internationally-known companies like Biogen, Vertex and Alnylam.
Dyax Corp., a biopharmaceutical corporation, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE.
Triumph Group, Inc. (NYSE:TGI), ended its Wednesday’s trading session with 8.45% gain, and closed at $65.06, after Triumph declared that the Board of Directors has designated Richard C. Ill as President and Chief Executive Officer and that Jeffry D. Frisby has stepped down as President and Chief Executive Officer and as a director of the corporation, effective /files/includes/pre-market-news-buzz-on-liberty-global-plc-class-c-ordinary-shares-nasdaqlbtyk-stmicroelectronics-nv-nysestm-spirit-realty-capital-nysesrc-fxcm-nysefxcm-1510428-right.js away. With this transition, director General Ralph E. Eberhart was named non-executive Chairman succeeding Executive Chairman Mr. Ill, the founder of the corporation, who will also remain a director.
The Triumph Board has formed a Search Committee comprised of independent directors and led by Richard C. Gozon, lead independent director, to identify a permanent CEO. The Committee will retain a leading executive recruiting firm, and internal and external candidates will be considered as part of the search process.
Triumph Group, Inc., through its auxiliaries, is engaged in the design, engineering, manufacture, repair, overhaul, and distribution of aero structures, aircraft components, accessories, subassemblies, and systems worldwide.
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.